These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11219973)

  • 1. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
    Diasio RB
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):21-6; discussion 27. PubMed ID: 11219973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Diasio RB
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
    Diasio RB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):23-7. PubMed ID: 9830621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-fluorouracil and dihydropyrimidine dehydrogenase.
    Kubota T
    Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [5-fluorouracil and dihydropyrimidine dehydrogenase].
    Kubota T
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
    Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
    Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
    Milano G; Etienne MC
    Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
    Milano G; Chamorey AL
    Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
    Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and clinical pharmacology of 5-fluorouracil.
    Schilsky RL
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):13-8. PubMed ID: 9830619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
    Li LH; Dong H; Zhao F; Tang J; Chen X; Ding J; Men HT; Luo WX; Du Y; Ge J; Tan BX; Cao D; Liu JY
    Eur J Cancer; 2013 May; 49(7):1752-60. PubMed ID: 23313143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
    Mattison LK; Soong R; Diasio RB
    Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
    Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
    Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
    Schilsky RL; Kindler HL
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
    Haaz MC; Fischel JL; Formento P; Renée N; Etienne MC; Milano G
    Cancer Chemother Pharmacol; 1996; 38(1):52-8. PubMed ID: 8603452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
    Milano G; Etienne MC
    Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.